Universal DX Presents Methylation Biomarker Data at AACR Special Conference: Precision Prevention, Early Detection, and Interception of Cancer
Retrieved on:
Thursday, November 17, 2022
Biotechnology, Technology, Health, Biometrics, Oncology, Health Technology, Research, Software, Genetics, Science, Clinical Trials, CRC, Transitive relation, Behavior, COAD, HR, Gene expression, Survival, Methylation, READ, News, Computational biology, TCGA, Nucleic acid thermodynamics, Liver, Algorithm, AUC, Neoplasm, The Cancer Genome Atlas, Machine learning, Interception, Patient, Gene, DNA, AA, KEGG, Biomarker, Research, Adenoma, AACR, Universal, Ephrin, Stomach, NAT, FGF, DX, Colorectal cancer, Plasma, Kaplan–Meier estimator, Medical imaging, Pharmaceutical industry, Cancer, PTPRO
This newest study underscores the robustness and validity of our previous results, by adding more biological value to the individual methylation marker regions, said Christian Hense, COO at Universal DX.
Key Points:
- This newest study underscores the robustness and validity of our previous results, by adding more biological value to the individual methylation marker regions, said Christian Hense, COO at Universal DX.
- Investigating their impact on gene expression and putting these biomarkers in the context of biological pathways allows for better understanding of the behavior of early cancer.
- Differential signal was observed between AA and NAT and CRC and adjacent normal tissue, indicating biological signal change with adenoma progression to cancer.
- Universal DX will present its findings live at the AACR special conference on Precisions, Prevention, Early Detection, and Interception of Cancer in Austin, TX November 17-19.